Vor Ort
Merkzettel Warenkorb
Produktbild: The Charnolosome as a Novel Nanothereranostic Biomarker

The Charnolosome as a Novel Nanothereranostic Biomarker Overcoming Future Challenges in Medicine

371,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

27.09.2024

Verlag

Elsevier Science & Technology

Seitenzahl

968

Maße (L/B)

27,6/21,6 cm

Gewicht

2530 g

Sprache

Englisch

ISBN

978-0-443-21752-4

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

27.09.2024

Verlag

Elsevier Science & Technology

Seitenzahl

968

Maße (L/B)

27,6/21,6 cm

Gewicht

2530 g

Sprache

Englisch

ISBN

978-0-443-21752-4

EU-Ansprechpartner

Zeitfracht Medien GmbH
Ferdinand-Jühlke-Straße 7
99095 Erfurt
DE
produktsicherheit@zeitfracht.de

Herstelleradresse

Elsevier Science & Technology
London Wall 125
EC2Y 5AS London
GB
tradeorders@elsevier.com

Ein neues Kapitel für Ihre Bücher

Ein neues Kapitel für Ihre Bücher

Schenken Sie Ihren alten Schätzen ein zweites Leben: Einfach Barcode scannen, Versandetikett ausdrucken, Bücher verschicken und Thalia Geschenkkarte erhalten.

Jetzt verkaufen
Jetzt verkaufen

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
Die Leseprobe wird geladen.
  • Produktbild: The Charnolosome as a Novel Nanothereranostic Biomarker

  • Section I: General Topics
    1. Transcriptional regulation of Charnolosome through gene/base-editing
    2. Charnolosome destabilization induces inflammasome activation
    3. Charnolosome in Charnoly Body molecular pathogenesis of gene-manipulated cells and animals
    4. Charnolosome and inflammasome in chronic MDR diseases
    5. Charnolosome stabilization inhibits inflammasome to confer personalized nanotheranostic benefit in chronic MDR diseases
    6. Endogenous, natural, and synthetic antioxidants stabilize charnolosome and its exocytosis to confer theranostic benefit by inflammasome inhibition
    7. Charnolosome stability index (stabilized Charnolosome vs activated inflammasome) determines normal cellular function to remain healthy
    8. Charnolosome stability index regulates Charnoly Body molecular pathogenesis
    9. Nanotheranostic significance of antioxidants in Charnolosome detoxification
    10. Theranostic significance of Charnolosome in personalized nanomedicine
    11. Environmental toxins and transcriptional regulation of Charnolosome
    12. Antioxidants-mediated Charnolosome transcriptional regulation in health and disease
    13. Mitochondrial bioenergetics, Charnosome, and theranostic potential of antioxidants
    14. Cellular, molecular, and genetic significance of metallothioneins as Charnolosome modulators
    15. Pharmacogenomics of metallothioneins and other endogenous, natural, and synthetic antioxidants as CS Regulators in health and disease
    16. Environmental pollution and metal ion speciation of metallothioneins
    17. Metallothioneins as potential charnolopharmacotherapeutics
    18. Antioxidants as Charnolosome stabilizers, charnolophagy enhancers, and intracellular detoxifiers.
    19. Charnolosomaging triggers inflammaging to induce charnoptosis, pyroptosis, and ferroptosis in chronic MDR diseases in aging
    20. Charnolosome as a theranostic biomarker in cell therapy and nanomedicine

    Section II: Special Topics
    Part 1: Malnutrition, Stress, Inflammation, Microbial Infections, and Ionizing Radiation Injuries
    21. Charnolosome in malnutrition
    22. Charnolosome in stress
    23. Charnolosome in inflammation
    24. Charnolosome in microbial infections
    25. Charnolosome in ionizing radiation injuries

    Part 2: Congenital & Metabolic Diseases
    26. Charnolosome in congenital diseases
    27. Charnolosome in metabolic diseases
    28. Charnolosome in hyperlipidemia
    29. Charnolosome in obesity
    30. Charnolosome in diabetes
    31. Charnolosome in hepatic diseases
    32. Charnolosome in GIT diseases

    Part 3: Multidrug-Resistant Systemic Diseases
    33. Charnolosome in skin diseases
    34. Charnolosome in musculo-skeletal diseases
    35. Charnolosome in pulmonary diseases
    36. Charnolosome in cardiovascular diseases
    37. Charnolosome in renal diseases
    38. Charnolosome in reproductive diseases

    Part 4: Neuropsychiatric & Neurodegenerative Diseases
    39. Charnolosome in polysubstance abuse
    40. Charnolosome in neuropsychiatric diseases
    41. Charnolosome in neurodegenerative diseases
    42. Charnolosome in Neurodegenerative ¿-Synucleinopathies
    43. Charnolosome in Parkinson's Disease
    44. Charnolosome in Alzheimer's Disease and other taupathies
    45. Charnolosome in stroke & traumatic brain injury
    46. Attenuation of Charnolosome-Mediated Neurodegenerative ¿-Synucleinopathies by antioxidants
    47. Charnolosome as a novel nanotheranostic biomarker of aging

    Part 5: Inflammatory Diseases, Autoimmune Diseases, Cancer, & Infectious Diseases
    48. Charnolosome in Inflammatory Diseases
    49. Charnolosome in autoimmune diseases
    50. Charnolosome in cancer
    51. Charnolosome in infectious diseases

    Section III: Future Prospects
    52. Charnolosomics in nanomedicine (Recent Update)
    53. Charnolosome-based disease-specific nanopharmacotherapeutics
    54. Physiological, Biochemical, Pharmacological, and Genetic Manipulation of Charnolosome in Personalized Nanotheranostics of Chronic MDR Diseases
    55. Transcriptional and translational regulation of Charnolosome in multi-drug resistant malignancies and other chronic diseases
    56. Future prospectus of Charnolosome in evidence-based personalized nanotheranostics